Will AbbVie Q3 Global Skyrizi revenues be above?

Currently, the prediction market odds reflect a collective assessment of whether AbbVie’s Q3 global Skyrizi net revenues will surpass the specified target. This differs from traditional analyst forecasts, which are typically based on modeling and individual research. This market aggregates the wisdom of the crowd, allowing for a dynamic and real-time evaluation of potential outcomes. While analyst opinions may offer valuable insights, the prediction market provides a continuously updated probability based on actual trading activity, potentially revealing divergences from conventional expectations regarding AbbVie’s performance.

On Polymarket, this market is priced through a continuous auction mechanism where traders buy and sell shares representing their belief about the outcome. The price of a share directly corresponds to the probability of the event occurring, as perceived by the market participants. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. As more traders participate and new information becomes available, the price adjusts accordingly, reflecting the evolving consensus. This creates a dynamic pricing system that is driven by supply and demand, and provides a real-time indication of market sentiment surrounding AbbVie’s Skyrizi revenue.

This market resolves around Oct 30, 2026, with the outcome confirmed once the official Q3 global Skyrizi net revenues reported by AbbVie are verifiable from credible public reporting. The resolution will be based on the reported net revenue figure, and the market will determine whether it is above or below the specified threshold. Traders will then be able to claim their winnings or acknowledge their losses based on the final outcome. The resolution process ensures a transparent and objective determination of the market’s result.

Several signals or events could significantly influence this market before resolution. Any news regarding AbbVie’s Skyrizi sales performance, including preliminary reports or updates from industry analysts, could cause price fluctuations. Furthermore, broader macroeconomic factors impacting the pharmaceutical industry or healthcare spending could also play a role. Unexpected clinical trial results related to Skyrizi or competitor products, or even changes in regulatory approvals, could also shift market sentiment. Finally, any significant announcements from AbbVie regarding their financial outlook or revenue projections could move this market considerably.